Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03674567
Title Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors FLX Bio, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS


No variant requirements are available.